PhoreMost unveils platform to streamline molecular glue drug discovery
Pharma Times
JULY 22, 2025
The data supports the platform’s potential to accelerate drug development programmes and expand the druggable proteome. Dr Benedict Cross, CTO, PhoreMost, said: “Molecular glues have now been established as an effective therapeutic modality, but these small molecule drugs have still largely only been found through serendipity.
Let's personalize your content